At ASTRO, Artera presented clinical validation data on its prostate cancer test in an Asian population,and showed how the test may complement gene expression-based approaches.

A UCLA study shows that a new treatment combining a radioactive drug with radiation therapy could help delay hormone therapy ...

Only men with prostate tumors of the luminal B subtype benefited from adding apalutamide to salvage radiation in the phase 2 ...

Dr. Sutera opened his talk by outlining that he would divide his presentation into three parts: first, defining MMAI; second, discussing its application in oligometastatic prostate cancer; and third, ...

Neighborhood disadvantage is associated with greater expression of stress-related genes that are linked to more aggressive prostate cancer. Men from disadvantaged neighborhoods have higher expression ...

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate ...

The core foundation of precision medicine, and in turn, precision oncology, is a personalized approach to treatment that focuses on targeting specific molecular features that impact how cancer cells ...

Researchers found that analyzing certain chemokine levels may help explain racial disparities in prostate cancer lethality, and that neutralizing such chemokines could potentially benefit prostate ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...